Biopharmaceutical firm Techniclone announced that the U.S. Patent Office has issued a new patent to the firm, extending the use of its tumor necrosis technology (TNT) to medical imaging applications.
Techniclone claims TNT is unique as a diagnostic agent because it can detect the necrotic tissue found at the core of most solid tumors. The firm believes TNT has great potential as an imaging and diagnostic agent, with broad applicability to different types of tumors. Techniclone, of Tustin, CA, plans to begin human clinical trials of the imaging agent in the near future.
By AuntMinnie.com staff writers
June 7, 2000
Copyright © 2000 AuntMinnie.com
